{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:27:52Z","timestamp":1760189272015},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":11286,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1981,9]]},"abstract":"<jats:p>1 In a single blind study seventeen patients with mild or moderate essential hypertension and normal renal function were treated with labetalol alone in increasing doses from 300 via 600 to 1200 mg daily. 2 Average supine BP (systolic\/diastolic) was reduced by 24\/19 mm Hg. Seven patients attained a diastolic BP less than or equal to Hg. A significant postural fall in systolic BP was recorded, but no symptomatic orthostatic hypotension occurred. 3 In twelve patients measurements of plasma volume (125I\u2010albumin), extracellular volume (82Br\u2010space) and glomerular filtration rate (51Cr\u2010EDTA clearance) on placebo and subsequently labetalol showed no systemic changes. 4 Side effects were few causing two withdrawals because of impotence and arthralgia. 5 It is concluded that monotherapy with labetalol results in clinically relevant, persistent and dose dependent reduction in BP in patients with mild or moderate essential hypertension, apparently without concomitant expansion of body fluid volumes or influence on glomerular filtration rate.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1981.tb01225.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T16:33:21Z","timestamp":1343320401000},"page":"349-353","source":"Crossref","is-referenced-by-count":22,"title":["Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension."],"prefix":"10.1111","volume":"12","author":[{"given":"S","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PE","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2125.1979.tb04768.x","article-title":"Labetalol in the treatment of patients wth hypertension and renal functional impairment","volume":"8","author":"BAILEY R.R.","year":"1979","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)91059-3"},{"key":"e_1_2_1_4_1","first-page":"149","volume-title":"Control mechanisms in essential hypertension","author":"BIRKENH\u00c4GER W.H.","year":"1976"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365517209084290"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197815040-00002"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb05813.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197204202861603"},{"key":"e_1_2_1_9_1","first-page":"71","article-title":"Influence of extracellular fluid volume on response to antihypertensive drugs","author":"FINNERTY F.A.","year":"1970","journal-title":"Circ. Res."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6017.1046"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.36.6.248"},{"key":"e_1_2_1_12_1","first-page":"79","article-title":"Long term treatment of moderate hypertension with the beta preceptor blocking agent metoprolol","volume":"10","author":"HANSSON B.\u2010G.","year":"1977","journal-title":"Eur. J. clin. Pharmac."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0440129"},{"key":"e_1_2_1_14_1","first-page":"308","article-title":"Changes in glomerular filtration rate during long\u2010term treatment with propranolol and peripheral vasodilators in patients with arterial hypertension","volume":"26","author":"IBSEN H.","year":"1979","journal-title":"Dan. med. Bull."},{"key":"e_1_2_1_15_1","first-page":"783s","article-title":"Comparative anti\u2010hypertensive effects of labetalol and the combination of oxprenolol and phentolamine","volume":"3","author":"JOHNSON B.F.","year":"1976","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04775.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.55.3.533"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365517009046208"},{"key":"e_1_2_1_19_1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1365-2125.1979.tb04774.x","article-title":"A double blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension","volume":"8","author":"McNEIL J.J.","year":"1979","journal-title":"Br. J. clin. Pharmac."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.32.5.643"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04776.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00898.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00558432"},{"key":"e_1_2_1_24_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.0954-6820.1969.tb01474.x","article-title":"Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide","volume":"196","author":"R\u00d8NNOV\u2010JESSEN V.","year":"1969","journal-title":"Acta med. Scand."},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00611897"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0430165"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04767.x"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(78)90017-6"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.37.1.54"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1978.tb107854.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1981.tb01225.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1981.tb01225.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:09:05Z","timestamp":1699718945000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1981.tb01225.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1981,9]]}},"alternative-id":["10.1111\/j.1365-2125.1981.tb01225.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1981.tb01225.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,9]]}}}